The Puget Sound Oncology Consortium (PSOC) has been a funded member of the Southwest Oncology Group (SWOG) since 1976. A multi-modality approach is utilized which includes: Pathology, Surgery, Chemotherapy, Radiation Therapy, Biological Response Modifier Therapy and Quality of Life evaluations for the aim of improving cancer treatment outcome and care. Overall objectives are prolongation of life, increased quality of life, decreased toxicities, and prolonged disease-free survival. Additional objectives include improvement in techniques of screening, early detection and prevention of cancer and the rapid transfer of innovative therapies from the laboratory to the clinic. PSOC is one of the largest SWOG member groups and altogether comprises a network of 21 hospital and medical centers throughout the Pacific Northwest (Alaska, Oregon, and Washington). The scientific agenda of PSOC is determined by disease-specific committees that have contributed four pilot studies to SWOG in the past grant period. PSOC has 29 investigators who coordinate or co-coordinate 51 studies and has 28 members who hold primary contributing authorship in 71 published reports of SWOG studies. PSOC supports a urological cancer outreach program (UCOP) as well as three SELECT sites. PSOC ranks in the top five in follow-up with a total caseload of 1,005 patients and averages an annual accrual from member and affiliates of about 130 patients. The Selenium and Vitamin E Trial has accrued 960 patients, the SELECT Ancillary Study accrued 191 patients, and the UCOP program accrued 43 patients in this past grant period. PSOC maintains autologous and allogeneic bone marrow transplant programs as well as an active stem cell transplant program. Cytogenetics laboratories at the University of Washington and at Swedish Medical Center are certified as submitting and reference laboratories. The Clinical Practices Committee formed by Saul E. Rivkin MD supports the evaluation of resource utilization and legislative/cost effectiveness issues for patients enrolled in SWOG studies. Membership increased during the current grant period with a total of 108 new physician members. PSOC members are active in administrative and scientific activities and are dedicated to support the goals of the Southwest Oncology Group.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA020319-37
Application #
8410567
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-01-01
Project End
2013-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
37
Fiscal Year
2013
Total Cost
$284,743
Indirect Cost
$79,123
Name
Swedish Medical Center, First Hill
Department
Type
DUNS #
079264420
City
Seattle
State
WA
Country
United States
Zip Code
98122
Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Ellis, Georgiana K; Barlow, William E; Gralow, Julie R et al. (2011) Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol 29:1014-21
Williamson, Stephen K; Moon, James; Huang, Chao H et al. (2010) Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 28:3330-5
Gold, Philip J; Goldman, Bryan; Iqbal, Syma et al. (2010) Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol 5:1472-6
Slovak, Marilyn L; Bedell, Victoria; Lew, Danika et al. (2010) Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Res Treat 119:391-8
Clark, Joseph I; Moon, James; Hutchins, Laura F et al. (2010) Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer 116:424-31

Showing the most recent 10 out of 217 publications